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Introduction
Cryptococcal meningitis (CM) is caused by an opportunistic 
encapsulated yeast, Cryptococcus neoformans. Despite 
recent expansion of antiretroviral treatment (ART) 
programmes in developing countries, CM remains a major 
opportunistic infection, and a leading cause of mortality 
in acquired immune deficiency syndrome (AIDS) patients.1 
CM has become the leading cause of community-acquired 
meningitis (ahead of tuberculous and bacterial meningitis), 
and if not treated correctly, has a significant mortality.2 In 
2009, the global incidence of CM ranged from 0.04-12% per 
year among persons living with human immunodeficiency 
virus (HIV)/AIDS. Sub-Saharan Africa had the highest yearly 
burden estimate (median incidence 3.2%, 720 000 cases, 
range 144  000-1.3 million). In regions with primarily less 
developed countries, the estimated case fatality was 55%. 
However, in sub-Saharan Africa, it was estimated to be 
70%.3
Medical audit is central to the process of continuous quality 
improvement. Quality of care is one of the pillars of clinical 
governance, the concept that refers to the accountability 
of a health care system to ensure the correct standard of 
care for its patients.4 Medical audits are not new in the HIV 
context.5-7
A CM audit at Northdale Hospital, Pietermaritzburg, 
KwaZulu-Natal, reviewed 18 CM cases diagnosed in 
July 2006.8 The key concerns were management of CM-
associated raised intracranial pressure (ICP), general CM 
management uncertainties, and follow-up challenges 
regarding ART and long-term fluconazole adherence. 
The key recommendations included addressing resource 
needs (manometers), paying attention to the diagnosis and 
management of raised ICP, and addressing the need to 
develop a local CM treatment guideline. 
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In a 2005 report from two hospitals in Washington, DC, USA, 
researchers emphasised the importance of adherence to the 
Infectious Diseases Society of America (IDSA) guidelines 
for CM management.9,10 Deviations in the management of 
raised ICP were observed in 88% of patients with poor 
neurological outcome. Aggressive management of raised 
ICP was associated with an improved outcome. This report 
recommends that measurement of ICP be performed in all 
patients evaluated for meningitis in treatment settings with 
a high prevalence of immunosuppression.
A recent South African guideline for CM, published in 
2007, stressed the importance of improving the initial acute 
management of CM, as this will maximise the patient’s 
chances of initial survival, and subsequent entry into the 
ART programme.11
CM patients are treated in the district and regional hospitals 
of the Cape Winelands (East) district. The clinical outcomes 
of these patients were perceived as poor by the treating 
team. However, no data were available to show whether 
the quality of care could explain these poor outcomes. 
In addition, no data were available to determine whether 
generalist care at a district hospital was comparable to 
specialist care at the regional hospital.
Prior to this study, an initial audit was performed in 2008 
at Worcester Regional Hospital. Target standards were 
developed for each criterion of the CM management 
process. These criteria had to be well defined, as well as 
measurable against a level of performance.12 The criteria 
were divided into three areas; structure, process and 
outcome. The audit of 14 patients’ records highlighted the 
following findings. Target standards for completing 14 days 
of amphotericin B and eight weeks of high-dose fluconazole, 
were met in this period (June 2007 until July 2008); opening 
pressures (manometry) with lumbar punctures were carried 
out in only three of the 14 patients; no cases of amphotericin 
B-associated renal impairment were found (at the time, 
the misperception among the clinical team was that 
amphotericin B caused renal impairment in most patients); 
and all the patients were referred for ART commencement, 
but none of the patients had started ART by the target 
standard (four weeks from onset of antifungal treatment). 
The clinical team admitted unfamiliarity regarding the use 
of manometry, and the management of CM-associated 
raised ICP. The insights from this prior audit provided the 
motivation for this study, and helped to define the initial 
interventions. 
Aim and objectives
This medical audit aimed to improve the quality of the 
clinical care of HIV-positive patients diagnosed with CM in 
the Cape Winelands (East) district by evaluating the clinical 
team’s adherence to national treatment guidelines. 
The objectives of the audit were as follows:
•	 To create appropriate target standards for the 
management aspects of CM.
•	 To demonstrate an improvement in the quality of CM 
care, using the cyclical audit process.
•	 To identify strengths and weaknesses in the quality of 
CM care at district and regional hospital level.
•	 To reflect on the quality of CM care at district hospital 
level, as compared to regional hospital level.
•	 To identify key interventions that may improve the 
quality of care of CM patients.
•	 To provide recommendations to the facilities and the 
Department of Health.
Method
Study design
The study followed the usual steps for medical audit as 
shown in Figure 1. Because of the information derived 
from a prior audit, described in the introduction, this study 
started the new audit cycle by implementing changes in 
clinical practice.
Setting
The study included all five hospitals in the eastern part of 
the Cape Winelands district. The Cape Winelands (East) 
district refers to the three subdistricts in the drainage area 
of Worcester Regional Hospital, Witzenberg (Ceres District 
Hospital), Breede Valley (Worcester Regional Hospital 
and Brewelskloof Tuberculosis Hospital), and Langeberg 
(Robertson and Montagu district hospitals). CM patients are 
admitted for in-patient amphotericin B treatment at all of 
these hospitals. On discharge, these patients are managed 
at various primary health care clinics in the drainage area 
of these hospitals. District hospitals are staffed by general 
medical practitioners, while the departments at the regional 
hospital and tuberculosis hospital are staffed by internal 
medicine specialists, and medical officers dedicated to the 
specific discipline. 
The audit team
Figure 1: Quality improvement cycle
Medical audit = Quality improvement
Plan care 
implement change
Agree criteria 
set target standards
Observe practice 
collect data
Evaluate information 
performance versus targets
Involve the  
practice team 
Choose topic
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The clinical audit team of the Cape Winelands (East) 
district consisted of the researchers, the district’s clinical 
programme co-ordinator for infection prevention and 
control, as well as audit champions from each of the 
subdistricts. The work of the audit team relied on the co-
operation of all relevant healthcare personnel (managers, 
doctors, nurses, pharmacists, laboratory technicians and 
ART clinic personnel) at the facilities. 
Step 1: Intervention: plan changes based on findings of 
the first audit cycle
Interventions were developed based on the results of the 
prior audit, which used the same methods as described here, 
but was confined to the regional hospital. During September 
and October 2009, the researchers arranged training 
sessions at each of the five hospitals. This educational 
intervention focused on the problem areas identified in the 
prior audit, especially the importance of adhering to the 
national treatment guidelines.11 It was reinforced by posters 
and handouts describing the CM treatment guidelines. The 
audit team also liaised with local hospital management to 
ensure the procurement of spinal manometers, and with 
the ART clinic staff to ensure the speedy attendance to CM 
patients.
Step 2: Revision of old, and development of new, 
criteria, and target standards
The target standards used in the prior audit were reviewed, 
and new criteria were included from the guidelines published 
in The South African Journal of HIV Medicine and other 
Table I: Comparison of actual performance and target standards (n= 25)
Criteria Target standard n Actual performance n (%) Target standard met
Structural criteria
1.1 Availability of amphotericin B per eligible patient 100% 20 15 (75) No
1.2 Availability of fluconazole per facility 100% 5 5 (100) Yes
1.3 Protocol for the administration of amphotericin B 
displayed in the facility
100% 5 4 (80) No
1.4 Availability of spinal manometers per facility 80% 5 2 (40) No
Process criteria
2.1
CT scan if depressed level of consciousness and 
focal neurology
100% 2 2 (100) Yes
2.2
Requesting CLAT on Indian ink-negative CSF 
samples
100% 8 8 (100) Yes
2.2 Use of CSF manometry in initial LPs 100% 25 11 (44) No
2.4
ICP reading and opening pressure recorded during 
admission (including initial LP) 
80% 25 20 (80) Yes
2.5
Completing target of 14 days of 
IV amphotericin B
80% 20 9 (45) No
2.6 Using correct dose of amphotericin B (1 mg/kg) 100% 20 19 (95) No
2.7
Adherence to minimum standard of renal monitoring: 
U and E, Mgg tests while on amphotericin B (initial 
and two tests per week)
100% 18 8 (44) No
2.8 Saline preload prior to daily amphotericin B dose 100% 20 17 (85) No
2.9 Saline IV flush after daily amphotericin B dose 100% 20 12 (60) No
2.10
Referral for inpatient ART counselling during 
admission
80% 11 9 (81) Yes
2.11 Referral to ART clinic on discharge 100% 8 8 (100) Yes
2.12
High-dose fluconazole for eight weeks (consolidation 
phase)
100% 7 7 (100) Yes
Outcome criteria
3.1
Commencement of ART by week four into antifungal 
treatment
80% 5 3 (60) No
3.2
Percentage developing amphotericin B-associated 
renal impairment
< 20% 20 3 (15) Yes
3.3
Percentage developing amphotericin B-associated 
thrombophlebitis
< 10% 20 2 (10) Yes
3.4 Two months survival post-diagnosis 60% 18 6 (33) No
CT: computed tomography, CLAT: cryptococcal latex agglutination test, CSF: cerebrospinal fluid, LP: lumbar punctures, ICP: intracranial pressure, IV intravenous, ART: antiretroviral treatment
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literature.11,13-16 The updated criteria and standards used in 
the audit cycle are listed in Table I.
Step 3: Collection of data to measure target standards
All HIV-positive patients aged 13 years and older who were 
diagnosed with CM and treated at the hospitals in the 
eastern part of the Cape Winelands district in the specified 
period, November 2009 to June 2010, were enrolled. 
Patients were identified by extracting diagnostic information 
from the National Health Laboratory Service database. 
Altogether, 25 patients were identified, and their folders 
reviewed.
Step 4: Analysis of the data, and comparison with 
target standards
The data were entered into MS Excel® and analysed to give 
simple frequencies. The results were then compared with 
the target standards for each criterion. Subgroup analysis 
was performed to enable comparison of the results for the 
regional vs. district hospitals. The results from this audit 
were also compared to the results obtained in the prior 
audit.
Ethical considerations 
The Health Research Ethics Committee of the Faculty 
of Health Sciences, Stellenbosch University, approved 
the study protocol on 8 December 2009 (N09/08/205). 
The study protocol (research proposal 2010 RP 89) was 
also approved by the district health services and health 
programmes, Provincial Government Western Cape.
Results 
The demographic and medical profiles of the 25 patients 
with CM are shown in Table II.
The results are presented in three sections: all hospitals, 
district vs. regional hospitals, and, finally, a comparison with 
the prior audit.
All hospitals
Table I presents the actual level of performance for each 
criterion for the whole audit population. This level is 
compared to the target standard. 
Of the 25 patients, four patients did not receive amphotericin 
B. Three died prior to initiating treatment, and one had prior 
renal impairment. One patient receiving amphotericin B was 
excluded, as this patient had only just been admitted at the 
time of data collection. Of the 20 who started amphotericin 
B treatment, nine completed the 14-day course, three 
died before completing treatment, five did not complete 
treatment due to a lack of amphotericin B in stock, and 
three stopped treatment because of renal impairment. 
Of the 25 patients, 14 were not expected to start ART; nine 
died in hospital, two were already on ART, and three had 
only just been admitted at the time of data collection. Of the 
remaining 11, three died before their ART clinic appointment, 
and the remaining eight should have initiated ART.
Twelve patients died in hospital, and one patient died soon 
after discharge. At the time of data collection, three patients 
were still receiving initial treatment in hospital. Data on the 
monitoring of amphotericin B were missing on two patients, 
and data on the status of two patients eight weeks post-
discharge were also missing.
District vs. regional hospitals
The data of six district-level patients and 14 regional-level 
patients, were used to analyse the differences in structure, 
process and outcome in CM management. The researchers 
excluded the data from Brewelskloof Hospital’s five patients 
for this comparison, as they were treated in a dedicated 
tuberculosis hospital, and not a district hospital. Table III 
compares the demographic and medical profile of these 
patients. 
Table IV compares the results from the district and regional 
hospitals. The target standard was met in both settings in 
seven criteria, and not met in both settings in eight criteria. 
Only the regional hospital met the target standard for three 
criteria: consistent availability of manometers, follow-up 
manometry, and occurrence of renal impairment during 
amphotericin B treatment. Only the district hospital met the 
target standard for two criteria, displaying the guidelines in 
the facility, and providing in-patients with ART counselling 
referrals. 
Table II: Demographic and medical profile of the study population
Male Female Total
Number of patients in audit 13 12 25
Average age (years) 40 33 37
Average CD4 count at CM diagnosis 
(cells/μl)
131 82 108
Average in-patient stay for those 
patients who were discharged (days)
40 28 34
Number of patients with previous 
diagnosis of CM
2 1 3
Number of patients already on ART at 
CM diagnosis
3 2 5
ART: antiretroviral treatment
Table III: Demographics: district vs. regional hospitals (2010 audit)
District Regional
Number of patients 6 14
Average age (years) 39 35
Average CD4 count at CM diagnosis  
(cells/μl)
105 108
Average in-patient stay (days) 20 26
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Comparison with prior audit
Only the data from the regional hospital could be compared 
with the prior audit results. The demographic and medical 
profiles of these patients are shown in Table V, while Table 
VI compares the actual results. Only the criteria from the 
2008 audit were used for this comparison. In both audits, 
the target standard was met in six criteria, and not met in an 
equal amount. In the 2010 audit, amphotericin B treatment 
was not available consistently. Although the criterion was 
still not met, the adherence to spinal manometry improved 
during the 2010 audit.
In the 2008 audit, three out of the 13 patients were already on 
ART before the CM diagnosis. Seven out of the 13 patients 
died before week 4 of antifungal treatment. Therefore, only 
three patients could be evaluated for the ART work-up 
criterion.
Table V: Demographics: Worcester Regional Hospital audits (2008 
and 2010)
2008 2010
Number of patients 13 14
Average age (years) 35 35
Average CD4 count at CM diagnosis (cells/μl) 110 108
Average in-patient stay (days) No data 26
Discussion 
The audit focused on the three key areas of the CM in-patient 
treatment period, namely CSF manometry, amphotericin B 
treatment and ART initiation and referral. The key issues 
and recommendations are very similar to those of the two 
audits in KwaZulu-Natal and Washington, DC mentioned in 
the introduction
Table IV: Results: comparison of level of performance: district vs. regional hospitals (2010 audit)
Criteria
Target 
standard 
District hospitals Regional hospital
n
Actual
performance  
n (%)
Target 
standard  
met n
Actual 
performance 
 n (%)
Target 
standard  
met
1.1 Availability of amphotericin B per eligible patient 100% 6 5 (83) No 10 6 (60) No
1.2 Availability of fluconazole per facility 100% 3 3 (100) Yes 1 1 (100) Yes
1.3
Protocol for the administration of amphotericin B 
displayed in the facility
100% 3 3 (100) Yes 1 0 (0) No
1.4 Availability of spinal manometers per facility 80% 3 0 (0) No 1 1 (100) Yes
2.1
CT scan if depressed level of consciousness and focal 
neurology
100% Nil patients met CT indications 1 1 (100) Yes
2.4 Requesting CLAT on Indian ink-negative CSF samples 100% 1 1 (100) Yes 3 3 (100) Yes
2.2 Use of CSF manometry in initial LPs 100% 6 1 (17) No 14 5 (36) No
2.3
ICP reading and opening pressure recorded during 
admission (including initial LP) 
80% 6 3 (50) No 14 13 (93) Yes
2.5 Completing target of 14 days of IV amphotericin B 80% 5 2 (40) No 11 5 (45) No
2.6
Using correct dose of amphotericin B 
(1 mg/kg)
100% 5 5 (100) Yes 11 10 (91) No
2.7
Adherence to minimum standard of renal monitoring: 
U and E, Mg tests while on amphotericin B (initial and 
two tests per week)
100% 5 2 (40) No 9 4 (44) No
2.8 Saline preload prior to daily amphotericin B dose 100% 5 4 (80) No 11 9 (81) No
2.9 Saline IV flush after daily amphotericin B dose 100% 5 2 (40) No 11 5 (45) No
2.10
Referral for in-patient ART counselling during 
admission
80% 3 3 (100) Yes 7 5 (71) No
2.11 Referral to ART clinic on discharge 100% 3 3 (100) Yes 5 5 (100) Yes
2.12
High-dose fluconazole for eight weeks (consolidation 
phase)
100% 3 3 (100) Yes 5 5 (100) Yes
3.1
Commencement of ART by week 4 into antifungal 
treatment
80% 3 1 (33) No 6 2 (33) No
3.2
Percentage developing amphotericin B-associated 
renal impairment
< 20% 5 2 (40) No 11 0 (0) Yes
3.3
Percentage developing amphotericin B-associated 
thrombophlebitis
< 10% 5 0 (0) Yes 11 1 (9) Yes
3.4 Two months survival post-diagnosis 60% 6 3 (50) No 9 2 (22) No
CT: computed tomography, CLAT: cryptococcal latex agglutination test, CSF: cerebrospinal fluid, LP: lumbar punctures, ICP: intracranial pressure, IV: intravenous, ART: antiretroviral treatment
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Spinal manometry was performed more consistently in the 
regional hospital than in the district hospitals, and spinal 
manometers were also more consistently available at the 
regional hospital. Spinal manometers were introduced to 
the district hospitals as part of the interventions, but were 
not readily available. At the regional hospital, the overall 
attention to spinal manometry had improved considerably 
between the prior and current audits. However, the use 
of manometry with the initial diagnostic lumbar puncture 
needs to be improved.
There were three main reasons for failing to reach the 14-
day amphotericin B target. These were patient deaths, 
drug stock problems and renal impairment. An unexpected 
finding was the interruption of treatment due to lack of 
amphotericin B stock, which requires further exploration 
at local and regional pharmaceutical treatment committee 
meetings.
The renal monitoring of amphotericin B treatment was also 
suboptimal, possibly due to lack of awareness of the need 
to monitor renal function. Saline preloading (prior to the daily 
amphotericin B dose) was carried out well in both settings. 
However, saline flushing of the line after the amphotericin 
B dose was poorly documented in both settings. Both 
settings reported a low prevalence of amphotericin 
B-related morbidity, such as amphotericin B-associated 
thrombophlebitis and renal impairment, but documentation 
of these side-effects was consistently inadequate in both 
settings. 
The in-patient referral for ART counselling was better in the 
district hospital setting. This may be due to the seamless 
nature of services in the district hospitals. However, both 
levels of care had difficulty in achieving the target of four 
weeks between the onset of amphotericin B and the onset 
of ART. Creative ways of commencing ART by week 4 
of antifungal treatment need to be explored by local role 
players. Patients with low functionality could be transferred 
to a step-down facility (subacute bed) for in-patient ART 
initiation. Community-based workers and families may 
support outpatient ART initiation in the patient’s home. 
Subdistrict-specific community resources should be 
explored.
The quality of care at district hospitals appeared comparable 
to that of the regional hospital, although higher risk patients 
should be referred from the district level. These negative 
predictive factors regarding mortality risk have been 
described in the literature as high CSF fungal burden, raised 
ICP, low CD4 count, and other co-morbid factors.17
The constant turnover of junior doctors in the hospitals may 
have limited the impact of the initial educational intervention, 
and the regional hospital did not display the guidelines as 
a wall poster.
An integrated care pathway functions as a tool to adapt best 
evidence to a particular setting, such as the district hospital 
context where CM patients are treated sporadically by 
generalist healthcare workers. This strategy of developing 
Table VI: Comparing of actual performance of Worcester Regional Hospital (2008 vs. 2010) to the target standards
Criteria from initial audit
Target  
standard
2008 2010
n
Actual 
performance  
n (%)
Target 
standard  
met
n
Actual 
performance 
 n (%)
Target  
standard  
met
1.1 Availability of amphotericin B per eligible patient 100% 9 9 (100) Yes 10 6 (60) No
1.2 Availability of fluconazole per facility 100% 1 1 (100) Yes 1 1 (100) Yes
1.3
Protocol for the administration of amphotericin B 
displayed in the facility
100% 1 0 (0) No 1 0 (0) No
2.1
CT scan if depressed level of consciousness and 
focal neurology
100% 4 4 (100) Yes 1 1 (100) Yes
2.2 Use of CSF manometry in all LPs 100% 13 3 (21) No 14 13 (93) No
2.4
Requesting CLAT on Indian ink-negative CSF 
samples
100% 13 13 (100) Yes 3 3 (100) Yes
2.5 Completing target of 14 days of IV amphotericin B 80% 9 7 (78) No 11 5 (45) No
2.7 Baseline U and E and biweekly U and E 100% 13 12 (92) No 9 4 (44) No
2.11 Referral to ART clinic on discharge 100% 7 7 (100) Yes 5 5 (100) Yes
2.12
High-dose fluconazole for eight weeks 
(consolidation phase)
100% 7 7 (100) Yes 5 5 (100) Yes
3.1
Commencement of ART by week four into 
antifungal treatment
80% 3 0 (0) No 6 2 (33) No
3.2
Percentage developing amphotericin 
B-associated renal impairment
< 20% 9 0 (0) Yes 11 0 (0) Yes
3.4 Two months survival post diagnosis 60% 13 6 (46) No 9 2 (22) No
CT: computed tomography, CSF: cerebrospinal fluid, CLAT: cryptococcal latex agglutination test, IV: intravenous, ART: antiretroviral treatment
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and disseminating local health district guidelines may be 
more effective than the passive dissemination of national 
or international guidelines.18 CM care is complicated, and 
requires a standardised approach, which could be improved 
by development of a local integrated care pathway. An 
integrated care pathway forms all, or part of, the clinical 
record, and could be used for a CM database and data 
register, which may improve the quality of data used for 
subsequent audits. This database may also be utilised for 
other forms of research, such as long-term follow-up and 
outcomes of CM patients after completion of the in-patient 
treatment phase. The two-month survival figure of CM 
patients was still below the sub-Saharan reference value.13 
Integrated care pathways have human resource implications, 
as all new staff will require induction, whereas current staff 
will require ongoing training.18,19 While the integrated care 
pathway acts as a template of the care to be provided, it is 
not intended to compromise clinical judgement. Integrated 
care pathways are dynamic documents that require periodic 
review, and change is to be expected as new evidence 
emerges.20
Limitations
Although all patients with CM were included in the audit, the 
total number was small, especially in some of the subgroups. 
The reliability of the results must be treated with caution 
when dealing with such small numbers. In addition, the data 
depended on accurate and complete record keeping by the 
medical staff, and this was often inadequate. The prior audit 
had slightly different criteria, and was only performed at the 
regional hospital. 
Recommendations
Patients should continue to be managed at the district 
hospital, and those with adverse risk factors should be 
referred to the regional hospital.
The researchers developed an integrated care pathway 
for the integrated care of CM patients (available from the 
corresponding author), which has been presented to the 
audit team, and accepted by the Cape Winelands district 
office (distributed as Circular No 27/2011 on 9/9/2011). 
The integrated care pathway is based on the South 
African HIV Clinician Society guidelines, and the recently 
published 2010 Infectious Diseases Society of America 
(IDSA) CM management guidelines.11,21 This integrated 
care pathway comprises a CM management flowchart, as 
well as a two-week in-patient calendar which should be 
part of the patient’s clinical notes. This calendar prompts 
the clinical team (doctors, nurses and ART councillors) to 
perform evidence-based actions in the three key areas 
of the in-patient treatment phase: CSF manometry and 
management of raised ICP, amphotericin B treatment, and 
ART counselling and referral.
Follow-up audit cycles are recommended to evaluate the 
influence of this integrated care pathway, as well as the 
adherence of clinicians to the integrated care pathway. A 
dedicated CM audit team is recommended, consisting 
of the family physicians and the HIV/AIDS Sexually 
Transmitted Diseases and Tuberculosis (HAST) programme 
co-ordinators at subdistrict and district level, as well as the 
principal physician at the regional hospital. This team should 
use the best level of evidence to review the integrated care 
pathway and audit criteria on an annual basis. Consultation 
with provincial and national experts, such as the South 
African HIV Clinician Society, and infectious diseases 
academic units may be necessary to ensure the appropriate 
recommendations for rural and resource-constrained 
settings.
Conclusion
Criteria were developed to assess the structure, process and 
outcome of care for CM. Despite an educational intervention, 
significant deficiencies in the quality of care remained. 
Spinal manometers were not available at the district 
hospitals, and initial manometry was poorly performed at 
both levels of care. Completion of amphotericin B treatment 
was limited by a lack of medication, patient deaths, and 
development of renal impairment. Renal monitoring was 
suboptimal. Counselling for ART was better in the district 
hospitals, but all facilities struggled to initiate ART within 
four weeks. There was no consistent improvement in care 
at the regional hospital between the prior and current audit 
cycles. An integrated care pathway document has been 
developed and adopted as policy. Its impact on the quality 
of care will be evaluated by a dedicated audit team in the 
future.
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